Michael Sacerdote
Biotech

Ambit Biosciences: One-Trick Pony With A Broken Leg

Flush with $85 million in cash from its May 2013 IPO, armed with an outstanding scientific hypothesis, staffed by a world expert on leukemia, and nearly through with phase 2 clinical trials, Ambit Biosciences (AMBI) seems to be on the fast track to success. At the end of May, the esteemed private equity firm Orbimed purchased almost 1.5 million shares. The stock has nearly doubled to $13.52 since the beginning of July. Citigroup has given the company a rating of Outperform. Yet despite these excellent optics, careful review of the science and the economics indicates that common shareholders will almost certainly lose money, and probably all of it.

AMBI data by YCharts

Ambit currently has four drugs in...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details